CytoSorbents’ STAR-T trial receives Health Canada regulatory approval

CytoSorbents has received regulatory approval from Health Canada allowing inclusion of Canadian sites into the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor – STAR-T – randomized, controlled trial. CytoSorbents’ product CytoSorb is approved in the EU and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb-ATR for antithrombotic drug removal during cardiothoracic surgery.